Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company. The dividend is payable on August 1, 2024, to stockholders of record at the close of business on July 5, 2024.
In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on September 3, 2024, to stockholders of record at the close of business on August 6, 2024.
About Bristol Myers Squibb Company
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, X (formerly Twitter), YouTube, Facebook, and Instagram.
YupMD.com, a premier telehealth platform, is transforming the weight loss industry by providing convenient, science-backed solutions for individuals seeking sustainable and effective results. Through its innovative approach, YupMD connects patients...
Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, today presents on its novel SKY-0515 small molecule RNA splicing modulator targeting Huntington's...
The official brand behind Prime Biome, a product developed under Bioventra's portfolio of advanced formulations, has issued a public advisory regarding unauthorized third-party resellers misrepresenting the product online. Reports indicate that...
Adventist Health Simi Valley is proud to announce the opening of its newly designed clinic, a major step forward in providing high-quality, accessible healthcare to the community. This new facility combines two former clinics into one streamlined...
iOncologi, Inc., a clinical-stage biopharmaceutical company focused on advancing immunotherapy platform technologies, today announced the acquisition of TargImmune Therapeutics, a biotechnology company specializing in novel tumor targeted...
Willow Biosciences Inc. ("Willow" or the "Company") , a biotechnology company focused on industrial manufacturing of ingredients, announces that it has entered into a definitive agreement dated March 14, 2025 (the "Agreement") with an...
